Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close change Change (%) Open High Low

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Latest news

Show more
Frances Wang 2025 May 05, 16:00

XRP news today: Ripple Launches First-of-Its-Kind $25M RLUSD Fund

Cryptocurrencies
Tommy Yap 2025 May 05, 16:00

Morning Note: Cautious Optimism on US-China Trade; AMD & Arista Reports Loom

Morning Note Tech
Tommy Yap 2025 May 04, 16:00

Morning Note: Palantir's Report in Focus; Stable Swiss CPI; US Services Data Due

Morning Note Tech
an alarm clock with an arrow going up and down
Tommy Yap 2025 May 03, 21:00

Week Ahead: Fed and BoE Interest Rate Announcements in the Spotlight

Forex Indices
Frances Wang 2025 Apr 29, 16:00

Tariff news today: Trump softens car tariffs, Amazon to display tariff costs

Fed
Tommy Yap 2025 Apr 29, 16:00

Morning Note: Aussie CPI Up Slightly; Canada GDP Looms; US PCE Watch

Morning Note AUD CAD
Frances Wang 2025 Apr 28, 16:00

Bond ETFs Performance 2025: Risk Factors Associated with Bond ETFs

ETFs
Tommy Yap 2025 Apr 28, 16:00

Morning Note: UK Food Costs Spike; Earnings Watch for Visa & Coke

Morning Note

Info

Spread

0.9573

Spread (%)

0.9503 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Tuesday

13:31 - 19:59

Monday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

25226842112

Shares Outstanding

240392992

Earnings Date (Next)

0000-00-00

instr__dividend_date

2022-06-17

instr__ex_dividend_date

2022-06-02

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

EPS

-3.14

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Markets.com Bonus Trading

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Markets.com Bonus Trading
Trustpilot